Um Estudo de Fase III do HMPL-760 em Combinação com R-GemOx Versus Placebo em Combinação com R-GemOx em DLBCL Recorrente/Refratório
Um Estudo Randomizado de Fase III, Duplamente Cego, Controlado Positivo para Avaliar a Eficácia, Segurança e Farmacocinética de HMPL-760 em Combinação com R-GemOx Versus Placebo em Combinação com R-GemOx em Doentes com Linfoma Difuso de Grandes Células B (DLBCL) Recorrente/Refratário
This is a Phase III randomized, double-blind, positive controlled study to evaluate the efficacy, safety, and pharmacokinetics of HMPL-760 in combination with R-GemOx versus placebo in combination with R-GemOx in patients with R/R DLBCL.
Visão geral do estudo
Status
Status
Condições
Condições
Intervenção / Tratamento
Intervenção / Tratamento
Descrição detalhada
The study phases include screening period, treatment period, safety observation period, PFS follow-up period, and OS follow-up period.
The target population of this study includes patients with DLBCL who are relapsed or refractory.
Tipo de estudo
Tipo de estudo
Inscrição (Estimado)
Inscrição
Estágio
Estágio
- Fase 3
Contactos e Locais
Contato de estudo
Contato de estudo
- Nome: Dongmei Chen, CPL
- Número de telefone: 86-21-20671794
- E-mail: dongmeic@hutch-med.com
Locais de estudo
-
-
-
Baoding, China
- Recrutamento
- Baoding NO.1 Central Hospital
-
Contato:
- Haiying Yao
- Número de telefone: 18617789030
- E-mail: haiyingyaobd@163.com
-
Investigador principal:
- Haiying Yao
-
Beijing, China
- Recrutamento
- Beijing GoBroad Hospital
-
Investigador principal:
- Kai Hu
-
Contato:
- Kai Hu
- Número de telefone: 15010390336
- E-mail: HK13610956245@163.com
-
Beijing, China
- Recrutamento
- BEIJING TONGREN HOSPITAL, Capital Medical University
-
Investigador principal:
- Liang Wang
-
Contato:
- Liang Wang
- Número de telefone: 15001108693
- E-mail: wangliangtrhos@126.com
-
Bengbu, China
- Recrutamento
- The First Affiliated Hospital of Bengbu Medical College
-
Contato:
- Yanli Yang
- Número de telefone: 13855249678
- E-mail: Yangyanli0702@126.com
-
Investigador principal:
- Yanli Yang
-
Changchun, China
- Recrutamento
- The First Hospital of Jilin University
-
Investigador principal:
- Ou Bai
-
Contato:
- Ou Bai
- Número de telefone: 13039046656
- E-mail: lbl2054@163.com
-
Changsha, China
- Recrutamento
- Hunan Cancer Hospital
-
Investigador principal:
- Hui Zhou
-
Contato:
- Hui Zhou
- Número de telefone: 13975879796
- E-mail: zhouhui9403@126.com
-
Changsha, China
- Recrutamento
- The Second Xiangya Hospital of Central South University
-
Investigador principal:
- Hongling Peng
-
Contato:
- Hongling Peng
- Número de telefone: 18900766137
- E-mail: Penghongling@aliyun.com
-
Changsha, China
- Recrutamento
- People's Hospital of Hunan Province
-
Contato:
- Can Liu
- Número de telefone: 137 8728 5260
- E-mail: 617170469@qq.com
-
Investigador principal:
- Can Liu
-
Chengdu, China
- Recrutamento
- West China Hospital of Sichuan University
-
Investigador principal:
- Liqun Zou
-
Contato:
- Liqun Zou
- Número de telefone: 18980601027
- E-mail: Clinical_Zou@163.com
-
Chengdu, China
- Recrutamento
- Sichuan Provincial People's Hospital
-
Contato:
- Xiaobing Huang
- Número de telefone: 18981838236
- E-mail: hxb_trial@163.com
-
Investigador principal:
- Xiaobing Huang
-
Chongqing, China
- Recrutamento
- The First Affiliated Hospital of Chongqing Medical University
-
Investigador principal:
- Xin Wang
-
Contato:
- Xin Wang
- E-mail: 925170788@qq.com
-
Chongqing, China
- Recrutamento
- Chongqing University Cancer Hospital
-
Investigador principal:
- Yao Liu
-
Contato:
- Yao Liu
- E-mail: liuyao101709@163.com
-
Fujian, China
- Recrutamento
- Quanzhou First Hospital.Fujian
-
Contato:
- Xiongpeng Zhu
- Número de telefone: 13805998581
- E-mail: xiongpengzhu@163.com
-
Investigador principal:
- Xiongpeng Zhu
-
Fuzhou, China
- Recrutamento
- Fujian Medical University Union Hospital
-
Investigador principal:
- Jianzhen Shen
-
Contato:
- Jianzhen Shen
- Número de telefone: 138 0955 2722
- E-mail: doctorsjz@163.com
-
Guangzhou, China
- Recrutamento
- Sun Yat-sen University Cancer Center
-
Investigador principal:
- Zhiming Li
-
Contato:
- Zhiming Li
- Número de telefone: 13719189172
- E-mail: lzmsysu@163.com
-
Guangzhou, China
- Recrutamento
- Guangdong Provincial People's Hospital
-
Contato:
- Xiaojuan Wei
- Número de telefone: 86 13560097145
- E-mail: jxw919@hotmail.com
-
Investigador principal:
- Xiaojuan Wei
-
Guangzhou, China
- Recrutamento
- ZhuJiang Hospital of Southern Medical University(The Second Clinical Medical College)
-
Investigador principal:
- Yuhua Li
-
Contato:
- Yuhua Li
- Número de telefone: 13533706656
- E-mail: liyuhua2011gz@163.com
-
Guiyang, China
- Recrutamento
- The Affiliated Hospital of Guizhou Medical University
-
Investigador principal:
- Yan Zhang
-
Contato:
- Yan Zhang
- Número de telefone: 86 18984155172
- E-mail: Zhangyan20010802@sina.com
-
Hangzhou, China
- Recrutamento
- Zhejiang Cancer Hospital
-
Investigador principal:
- Haiyan Yang
-
Contato:
- Haiyan Yang
- E-mail: 2054451461@qq.com
-
Hangzhou, China
- Recrutamento
- The First Affiliated Hospital, Zhejiang University
-
Investigador principal:
- Zhen Cai
-
Contato:
- Zhen Cai
- Número de telefone: 13857190311
- E-mail: czclinicaltrial@163.com
-
Harbin, China
- Recrutamento
- Harbin Medical University Cancer Hospital
-
Contato:
- Qingyuan Zhang
- Número de telefone: 13313612989
- E-mail: sy86298276@163.com
-
Investigador principal:
- Qingyuan Zhang
-
Hefei, China
- Recrutamento
- The Second Affiliated Hospital of Anhui Medical University
-
Contato:
- Zhimin Zhai
- Número de telefone: 13855147434
- E-mail: zzzm889@163.com
-
Investigador principal:
- Zhimin Zhai
-
Jinan, China
- Recrutamento
- Qilu Hospital of Shandong University
-
Contato:
- Shuqian Xu
- Número de telefone: 18560087013
- E-mail: yoyoshuqian@126.com
-
Investigador principal:
- Shuqian Xu
-
Jinan, China
- Recrutamento
- Shandong Cancer Hospital & Institute
-
Investigador principal:
- Zengjun Li
-
Contato:
- Zengjun Li
- Número de telefone: 15735178591
- E-mail: zengjunli@163.com
-
Kunming, China
- Ainda não está recrutando
- The First Affiliated Hospital of Kunming Medical University
-
Contato:
- Mingxia Shi
- Número de telefone: 86 138 8806 0581
- E-mail: shmxia2002@sina.com
-
Investigador principal:
- Mingxia Shi
-
Nanchang, China
- Recrutamento
- Jiangxi Cancer Hospital
-
Investigador principal:
- Yan Huang
-
Contato:
- Yan Huang
- E-mail: 29265061@qq.com
-
Nanjing, China
- Recrutamento
- Jiangsu Cancer Hospital
-
Investigador principal:
- Yan Zhang
-
Contato:
- Yan Zhang
- Número de telefone: 13914712395
- E-mail: zhangyan1106@njmu.edu.cn
-
Nanjing, China
- Recrutamento
- Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School
-
Contato:
- Jingyan Xu
- Número de telefone: 86 13951969610
- E-mail: xjy1967@sina.com
-
Investigador principal:
- Jingyan Xu
-
Nanning, China
- Recrutamento
- The First Affiliated Hospital of Guangxi Medical University
-
Investigador principal:
- Zhigang Peng
-
Contato:
- Zhigang Peng
- E-mail: 2557382235@qq.com
-
Qingdao, China
- Recrutamento
- The Affiliated Hospital of Qingdao University
-
Contato:
- Xia Zhao
- Número de telefone: 18661803088
- E-mail: Zhaoxia@qdu.edu.cn
-
Investigador principal:
- Xia Zhao
-
Shanghai, China
- Recrutamento
- Ruijin Hospital, Shanghai Jiaotong University School of Medicine
-
Investigador principal:
- Weili Zhao
-
Contato:
- Weili Zhao
- Número de telefone: 86 13512112076
- E-mail: zwl_trial@163.com
-
Shanghai, China
- Recrutamento
- Tongji Hospital of Tongji University
-
Contato:
- Ping Li
- Número de telefone: 13564181131
- E-mail: lilyforever76@126.com
-
Investigador principal:
- Ping Li
-
Shanghai, China
- Ainda não está recrutando
- Tong Ren Hospital Shanghai Jiao Tong University School Of Medicine
-
Investigador principal:
- Ligen Liu
-
Contato:
- Ligen Liu
- Número de telefone: 86 18017337037
- E-mail: llg3532@shtrhospital.com
-
Shenyang, China
- Recrutamento
- Shengjing Hospital of China Medical University
-
Investigador principal:
- Wei Yang
-
Contato:
- Wei Yang
- Número de telefone: 18940251012
- E-mail: sjyangw@163.com
-
Shenzhen, China
- Recrutamento
- Shenzhen people's hospital
-
Investigador principal:
- Jihao Zhou
-
Contato:
- Jihao Zhou
- Número de telefone: 86 18718678693
- E-mail: zhoujihao@aliyun.com
-
Taiyuan, China
- Recrutamento
- Shanxi Provincial Cancer Hospital
-
Investigador principal:
- Liping Su
-
Contato:
- Liping Su
- Número de telefone: 13835158122
- E-mail: slpsy2022@163.com
-
Tangshan, China
- Recrutamento
- North China University of Science and Technology Affiliated Hospital
-
Contato:
- Zhenyu Yan
- Número de telefone: 15931508262
- E-mail: hbyzy2011@163.com
-
Investigador principal:
- Zhenyu Yan
-
Tianjin, China
- Recrutamento
- Tianjin Medical University Cancer Institute & Hospital
-
Investigador principal:
- Zhengzi Qian
-
Contato:
- Zhengzi Qian
- Número de telefone: 13702031222
- E-mail: qzz@163.com
-
Tianjin, China
- Recrutamento
- Tianjin People's Hospital
-
Contato:
- Xingli Zhao
- Número de telefone: 13752255454
- E-mail: insectzhao@163.com
-
Investigador principal:
- Xingli Zhao
-
Tianjin, China
- Recrutamento
- Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College
-
Investigador principal:
- Dehui Zou
-
Contato:
- Dehui Zou
- Número de telefone: 13602100955
- E-mail: zoudehui@ihcams.ac.cn
-
Wenzhou, China
- Recrutamento
- The First Affiliated Hospital of WMU
-
Contato:
- Songfu Jiang
- Número de telefone: 86 15305770033
- E-mail: jiangsongfu@189.cn
-
Investigador principal:
- Songfu Jiang
-
Wuhan, China
- Recrutamento
- Hubei Cancer Hospital
-
Investigador principal:
- Huijing Wu
-
Contato:
- Huijing Wu
- E-mail: 3269614878@qq.com
-
Wuhan, China
- Recrutamento
- Wuhan Union Hospital of China
-
Investigador principal:
- Liling Zhang
-
Contato:
- Liling Zhang
- Número de telefone: 15871725926
- E-mail: lily1228@sina.com
-
Xi'an, China
- Recrutamento
- The First Affiliated Hospital of Xi'an Jiaotong University
-
Investigador principal:
- Pengcheng He
-
Contato:
- Pengcheng He
- Número de telefone: 18991232609
- E-mail: hepc_gcp@163.com
-
Xi'an, China
- Recrutamento
- The Second Affiliated Hospital of Xi'an Jiaotong University (Xibei Hosiptal)
-
Investigador principal:
- Jie Liu
-
Contato:
- Jie Liu
- Número de telefone: 86 18092662371
- E-mail: lieujie@163.com
-
Xiamen, China
- Ainda não está recrutando
- The First Affiliated Hospital of Xiamen University
-
Investigador principal:
- Bing Xu
-
Contato:
- Bing Xu
- Número de telefone: 86 18750918842
- E-mail: xubingzhangjian@126.com
-
Xuzhou, China
- Recrutamento
- The Affiliated Hospital of Xuzhou Medical University
-
Contato:
- Wei Sang
- Número de telefone: 86 13645207648
- E-mail: 13645207648@126.com
-
Investigador principal:
- Wei Sang
-
Zhengzhou, China
- Recrutamento
- Henan Cancer Hospital
-
Investigador principal:
- Keshu Zhou
-
Contato:
- Keshu Zhou
- Número de telefone: 13674902391
- E-mail: dr_zkshu23810@163.com
-
Zhengzhou, China
- Recrutamento
- The First Affiliated Hospital of Zhengzhou University
-
Contato:
- Xudong Zhang
- Número de telefone: 13633825183
- E-mail: feverxxd@126.com
-
Investigador principal:
- Xudong Zhang
-
Ürümqi, China
- Recrutamento
- People's Hospital of Xinjiang Uygur Autonomous Region
-
Investigador principal:
- Yan Li
-
Contato:
- Yan Li
- Número de telefone: 86 13639935315
- E-mail: liyan232917@139.com
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, China
- Recrutamento
- Fudan University Shanghai Cancer Center
-
Contato:
- Fangfang Lv
- Número de telefone: 18017312613
- E-mail: Lvff80@163.com
-
Investigador principal:
- Fangfang Lv
-
-
Critérios de participação
Critérios de elegibilidade
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Sign the ICF and be able to follow the requirements of study protocol;
- Age ≥18 years;
- ECOG performance status score between 0 and 2;
- Histopathologically confirmed diagnosis of DLBCL;
- The investigator judges that the patient's current condition requires further treatment;
- Patients should have at least one bi-dimensionally measurable lesion;
- Expected survival is more than 12 weeks;
Exclusion Criteria:
- Patients with known primary or secondary central nervous system lymphoma (CNSL) or the presence of clinical symptoms suggestive of CNSL;
- Women who are pregnant (positive pregnancy test during the screening period) or breastfeeding;
- Organ insufficiency;
- Currently known history of liver disease, including cirrhosis, alcoholic liver, known active infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV);
- History of significant organ bleeding, including gastrointestinal bleeding, hematencephalon, haemoptysis, etc., within 8 weeks prior to the first dose of study drug;
- Known risk of bleeding, such as coagulation factor deficiency, vascular hemophilia; or the patient is receiving vitamin K antagonist (warfarin);
- The toxic reactions of previous anti-tumor therapy have not recovered to the level of ≤ grade 1 (except for alopecia and decreased appetite and other conditions that have been clearly required in the inclusion and exclusion criteria);
- Clinically significant active infection;
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Quadruplicar
Número de braços
Armas e Intervenções
Grupo de Participantes / BraçoGrupo de Participantes / Braço |
Intervenção / TratamentoIntervenção / Tratamento |
|---|---|
|
Experimental: The experimental group
Patients will receive HMPL-760 once daily (QD) orally in combination with R-GemOx regimen in 21-day cycles for a total of 8 cycles. Rituximab 375 mg/m2 IV is given on Day 1 of each cycle, and gemcitabine 1000 mg/m2 IV followed by oxaliplatin 100 mg/m2 IV is given on Day 2 of each cycle. |
Patients will receive HMPL-760 once daily (QD) orally. R-GemOx regimen in 21-day cycles for a total of 8 cycles. Rituximab 375 mg/m2 IV is given on Day 1 of each cycle, and gemcitabine 1000 mg/m2 IV followed by oxaliplatin 100 mg/m2 IV is given on Day 2 of each cycle.
Outros nomes:
|
|
Comparador de Placebo: The control group
Placebo QD at the same dose as HMPL-760 in the experimental group will be given in the control group, and the combination therapy is the same as in the experimental group. |
R-GemOx regimen in 21-day cycles for a total of 8 cycles. Rituximab 375 mg/m2 IV is given on Day 1 of each cycle, and gemcitabine 1000 mg/m2 IV followed by oxaliplatin 100 mg/m2 IV is given on Day 2 of each cycle.
Outros nomes:
Patients will receive HMPL-760 placebo once daily (QD) orally. |
O que o estudo está medindo?
Medidas de resultados primários
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Progression-free survival (PFS)
Prazo: Up to approximately two years
|
Investigator-assessed progression-free survival (PFS) Efficacy is evaluated using the Lugano Efficacy Evaluation Criteria for Malignant Lymphoma (Cheson 2014). PFS is defined as the time from randomization to PD or death due to any cause, whichever occurs first. |
Up to approximately two years
|
|
End of treatment (EOT)
Prazo: Up to approximately two years
|
Tumor assessment data will continue to be collected. Tumor assessment data collected after end of treatment (EOT) will be used. Tumor assessment data collected during the study and after EOT will be included in the PFS analysis (treatment policy strategy). |
Up to approximately two years
|
|
Systemic antitumor therapy
Prazo: Up to approximately two years
|
Use of other systemic antitumor therapy before PD or death (in the absence of PD):Tumor assessment after use of other systemic antitumor therapy will not be included in the analysis. For patients using other anti-tumor therapy before PD or death (in absence of PD), PFS will be censored at the last evaluable tumor assessment before the use of other systematic anti-tumor therapy (hypothetical strategy). |
Up to approximately two years
|
|
Overall survival (OS)
Prazo: Up to approximately two years
|
OS is defined as the time from randomization to death due to any cause. |
Up to approximately two years
|
|
systematic anti-tumor therapy
Prazo: Up to approximately two years
|
OS data will continue to be collected after the other systematic anti-tumor therapy, and the OS data collected before and after other systematic anti-tumor therapy will be included in analysis (treatment policy strategy). |
Up to approximately two years
|
|
Premature withdrawal from study treatment
Prazo: Up to approximately two years
|
OS data will continue to be collected after the patient's premature withdrawal from study treatment, and the OS data collected during the study treatment and after EOT will be included in analysis (treatment policy strategy). |
Up to approximately two years
|
Medidas de resultados secundários
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Independent review committee (IRC)-assessed PFS
Prazo: Up to approximately two years
|
Efficacy is evaluated using the Lugano Efficacy Evaluation Criteria for Malignant Lymphoma (Cheson 2014). |
Up to approximately two years
|
|
IRC- and investigator-assessed objective response rate (ORR)
Prazo: Up to approximately two years
|
Objective Response Rate (ORR) is defined as the ratio of patients who reached complete response (CR) or partial response (PR) |
Up to approximately two years
|
|
IRC- and investigator-assessed complete response rate (CRR)
Prazo: Up to approximately two years
|
Complete response (CR) rate is defined as the ratio of patients with who reached complete response (CR) |
Up to approximately two years
|
|
IRC- and investigator-assessed duration of response (DoR)
Prazo: Up to approximately two years
|
For patients who reached complete response (CR) or partial response (PR), Duration of Response (DoR) is defined as the time from the first CR or PR until disease progression or death due to any cause, whichever occurs first |
Up to approximately two years
|
|
IRC- and investigator-assessed clinical benefit rate (CBR)
Prazo: Up to approximately two years
|
Defined as the ratio of patients with complete response (CR), partial response (PR), or stable disease (SD) |
Up to approximately two years
|
|
IRC- and investigator-assessed time to response (TTR)
Prazo: Up to approximately two years
|
Time To Response (TTR) is defined as the time from the start of treatment to the first objective response rate (ORR) |
Up to approximately two years
|
|
Safety Endpoints
Prazo: Up to approximately two years
|
|
Up to approximately two years
|
|
PK characteristics of HMPL-760 in patients with R/R DLBCL when administered in combination with R-GemOx
Prazo: At the end of Cycle 4 (each cycle is 21 days)]
|
including but not limited to steady-state plasma concentrations of HMPL-760 pre-dose [trough concentrations (Ctrough)] and post-dose (C1h and C2h); If possible, a population pharmacokinetic (PPK) model can be used to generate PK parameters. If necessary, it can also be combined with other studies for model analysis. If possible, a population pharmacokinetic (PPK) model can be used to generate PK parameters. If necessary, it can also be combined with other studies for model analysis. |
At the end of Cycle 4 (each cycle is 21 days)]
|
Outras medidas de resultado
Outras medidas de resultado
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Biomarker assessment
Prazo: Up to approximately two years
|
Detect tumor driver gene mutations in tissue and blood samples, such as MYD88 and CD79B, etc, and explore the relationship between their mutation status and drug efficacy. |
Up to approximately two years
|
|
To explore the metabolite profile of HMPL-760 in combination with R-GemOx in tumor patients
Prazo: Up to approximately two years
|
Human metabolites of HMPL-760 when co-administered with R-GemOx |
Up to approximately two years
|
|
Pharmacokinetic parameters of gemcitabine and oxaliplatin when combined with HMPL-760
Prazo: Up to approximately two years
|
maximum concentration in steady-state (Cmax,ss) |
Up to approximately two years
|
|
Pharmacokinetic parameters of gemcitabine and oxaliplatin when combined with HMPL-760
Prazo: Up to approximately two years
|
time to maximum concentration in steady-state (Tmax,ss) |
Up to approximately two years
|
|
Pharmacokinetic parameters of gemcitabine and oxaliplatin when combined with HMPL-760
Prazo: Up to approximately two years
|
Area Under the Curve at steady state refers to the area under the plasma concentration-time curve during a dosing interval at steady state conditions (AUC,ss) |
Up to approximately two years
|
|
Pharmacokinetic parameters of gemcitabine and oxaliplatin when combined with HMPL-760
Prazo: Up to approximately two years
|
The rate at which the drug is eliminated from the body (CL/F) (if applicable ) |
Up to approximately two years
|
|
Pharmacokinetic parameters of gemcitabine and oxaliplatin when combined with HMPL-760
Prazo: Up to approximately two years
|
The distribution volume calculated based on the terminal elimination phase (Vz/F )(if applicable) |
Up to approximately two years
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Investigadores
Investigadores
- Investigador principal: Weili Zhao, Ruijin Hospital
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Início do estudo
Conclusão Primária (Estimado)
Conclusão Primária
Conclusão do estudo (Estimado)
Conclusão do estudo
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Primeira postagem
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última Atualização Postada
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
- Neoplasias
- Doenças do sistema imunológico
- Neoplasias por Tipo Histológico
- Doenças Linfáticas
- Distúrbios Linfoproliferativos
- Distúrbios imunoproliferativos
- Linfoma Não-Hodgkin
- Linfoma de Células B
- Linfoma
- Doenças hemic e linfáticas
- Linfoma de Células B Grandes Difuso
- Aminoácidos, peptídeos e proteínas
- Proteínas
- Produtos químicos orgânicos
- Compostos heterocíclicos, 1 anel
- Compostos heterocíclicos
- Terapêutica
- Rotas de administração de medicamentos
- Terapia medicamentosa
- Anticorpos, monoclonais
- Anticorpos
- Imunoglobulinas
- Imunoproteínas
- Proteínas sanguíneas
- Globulinas de soro
- Globulins
- Complexos de coordenação
- Desoxicitidina
- Citidina
- Nucleosídeos de pirimidina
- Pirimidinas
- Anticorpos, monoclonais, derivados de murinos
- Oxaliplatina
- Rituximabe
- Gemcitabina
- Injeções
Outros números de identificação do estudo
Outros números de identificação do estudo
- 2025-760-00CH1
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .